文献速递角膜与眼表疾病

碳青霉烯耐药铜绿假单胞菌角膜炎的临床特征与治疗结局

Clinical Features and Treatment Outcomes of Carbapenem-Resistant Pseudomonas aeruginosa Keratitis.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

该回顾性观察病例系列纳入2022年1月1日至2023年10月31日在Bascom Palmer眼科研究所就诊的9例多重耐药铜绿假单胞菌角膜炎患者,所有样本均检出exoU及碳青霉烯耐药blaVIM、blaGES基因,体外实验显示RB-PDAT具有潜在应用价值,2例接受RB-PDAT辅助抗生素治疗者视力结局改善。

要点

  • 9例多重耐药铜绿假单胞菌角膜炎患者中,全部样本检出exoU及blaVIM、blaGES基因。
  • 体外实验显示RB-PDAT对多重耐药铜绿假单胞菌角膜炎具有潜在治疗应用。
  • 2例患者接受RB-PDAT作为抗生素辅助治疗,视力结局改善。

核心结论

  • 本病例系列凸显铜绿假单胞菌耐药性与毒力的进展令人担忧,并强调需探索RB-PDAT等具有广谱覆盖且无已知抗生素耐药性的替代疗法。
  • 研究结果支持进一步探究RB-PDAT对其他多重耐药微生物的潜在效果。

研究设计与样本

  • 回顾性观察病例系列,纳入2022年1月1日至2023年10月31日在Bascom Palmer眼科研究所就诊、多重耐药铜绿假单胞菌角膜炎检测阳性的9例40岁及以上患者。

主要发现

  • 9例患者(5女4男;平均[SD]年龄73.4[14.0]岁)所有样本均检出exoU及碳青霉烯耐药blaVIM和blaGES基因。
  • 分离株经最低抑菌浓度检测显示对碳青霉烯类耐药。
  • 体外实验显示RB-PDAT对难治性病例具有潜在应用价值。
  • 2例患者接受RB-PDAT作为抗生素治疗的辅助,视力结局改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evaluation of the microbiological diagnostic profile of multidrug-resistant Pseudomonas aeruginosa keratitis and potential management with rose bengal-photodynamic antimicrobial therapy (RB-PDAT) is important. OBJECTIVE: To document the disease progression of carbapenemase-resistant P aeruginosa keratitis after an artificial tear contamination outbreak. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observation case series included 9 patients 40 years or older who presented at Bascom Palmer Eye Institute and had positive test results for multidrug-resistant P aeruginosa keratitis between January 1, 2022, and October 31, 2023. MAIN OUTCOMES AND MEASURES: Evaluation of type III secretion phenotype, carbapenemase-resistance genes blaGES and blaVIM susceptibility to antibiotics, and in vitro and in vivo outcomes of RB-PDAT against multidrug-resistant P aeruginosa keratitis. RESULTS: Among the 9 patients included in the analysis (5 women and 4 men; mean [SD] age, 73.4 [14.0] years), all samples tested positive for exoU and carbapenemase-resistant blaVIM and blaGES genes. Additionally, isolates were resistant to carbapenems as indicated by minimum inhibitory concentration testing. In vitro efficacy of RB-PDAT indicated its potential application for treating recalcitrant cases. These cases highlight the rapid progression and challenging management of multidrug-resistant P aeruginosa. Two patients were treated with RB-PDAT as an adjuvant to antibiotic therapy and had improved visual outcomes. CONCLUSIONS AND RELEVANCE: This case series highlights the concerning progression in resistance and virulence of P aeruginosa and emphasizes the need to explore alternative therapies like RB-PDAT that have broad coverage and no known antibiotic resistance. The findings support further investigation into the potential effects of RB-PDAT for other multidrug-resistant microbes.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tribin FE, Lieux C, Maestre-Mesa J, et al. Clinical Features and Treatment Outcomes of Carbapenem-Resistant Pseudomonas aeruginosa Keratitis. JAMA Ophthalmol. 2024. PMID: 38512246. doi:10.1001/jamaophthalmol.2024.0259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。